Regeneron Pharmaceuticals
Price & Volume
Stats
See more52W Range | $474.60-$820.12 |
Market Cap | $79.1B |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $14.3B |
Revenue Growth (YoY) | 2.5% |
Gross Profit (12 Mos) | $6.3B |
Diluted EPS | $41.49 |
News
See moreYahoo Finance • 9 hours ago
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Yahoo Finance • 9 hours ago
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Yahoo Finance • 9 hours ago
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
Yahoo Finance • 11 hours ago
Telix And Regeneron Partner To Advance Next-Generation Radiopharmaceutical Therapies
About
CEO | Dr. Leonard S. Schleifer M.D., Ph.D. |
CFO | Mr. Christopher R. Fenimore CPA |
Address | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 15,410 |
